Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-153

Reducing the trial number should certainly reduce the cost of the trial, but it does come with risks not least that they have to get sign off from the regulators on this change. Smaller patient number increase the risk that the trial won't reach a statistically valid endpoint even if the data is overall encouraging. We really need more details.

I am not suggesting that all is lost with IXC as the science they have is compelling, just that things are very uncertain at this point. Hopefully over the next few months we will get more details and a clear plan forward and at that point we can all assess the investment potential. In the mean time IXC is in the hands of the traders.